1.
Baseline characteristics before propensity-score-matched stratification by regimens
| Characteristics | PPCT (n=309) [n (%)] | Bev+PPCT (n=106) [n (%)] | P |
| ECOG PS, Eastern Cooperative Oncology Group Performance Score; EGFR, epidermal growth factor receptor; PPCT, platinum-pemetrexed-based chemotherapy; Bev, bevacizumab. | |||
Age (
 ) (year)
|
56.3±10.3 | 56.2±10.2 | 0.989 |
| ≥60 years | 123 (39.8) | 43 (40.6) | 0.909 |
| Male | 168 (54.4) | 49 (46.2) | 0.176 |
| ECOG PS | 0.082 | ||
| 0−1 | 288 (93.2) | 102 (96.2) | |
| ≥2 | 21 (6.8) | 4 (3.8) | |
| Smoking history | 0.338 | ||
| No | 185 (59.9) | 72 (67.9) | |
| Yes | 124 (40.1) | 34 (32.1) | |
| Comorbidities | 0.082 | ||
| Hypertension | 61 (19.7) | 16 (15.1) | |
| Diabetes mellitus | 23 (7.4) | 3 (2.8) | |
| Cardiovascular disease | 12 (3.9) | 3 (2.8) | |
| Thrombotic disease | 1 (0.3) | 1 (0.9) | |
| Cerebrovascular disease | 4 (1.3) | 3 (2.8) | |
| Other | 57 (18.4) | 28 (26.4) | |
| Baseline histology | 0.914 | ||
| Adenocarcinoma | 301 (97.4) | 103 (97.2) | |
| Large-cell carcinoma | 1 (0.3) | 0 (0) | |
| Bronchoalveolar carcinoma | 1 (0.3) | 0 (0) | |
| Mixed | 6 (2.0) | 3 (2.8) | |
| Sensitizing driven mutation | |||
| EGFR positive | 99 (32.0) | 28 (26.4) | 0.285 |
| T790M positive | 6 (1.9) | 2 (1.9) | 0.668 |
| ALK positive | 19 (6.1) | 8 (7.5) | 0.380 |
| C-MET positive | 3 (0.9) | 1 (0.9) | 0.730 |
| ROS-1 positive | 2 (0.6) | 0 (0) | 0.554 |
| Pemetrexed regimens | 309 (100) | 106 (100) | − |
| Brain metastases | 46 (14.9) | 13 (12.3) | 0.312 |
| Pleural invasion | 92 (29.8) | 43 (40.6) | 0.028 |
| Weight loss >5% | 22 (7.1) | 5 (4.7) | 0.269 |
| History of hemoptysis | 26 (8.4) | 7 (6.6) | 0.359 |
| Maintenance therapy | 132 (42.7) | 68 (64.2) | 0.001 |
| Previous surgery | 33 (10.7) | 22 (20.8) | 0.008 |
| Radiotherapy history | 43 (13.9) | 22 (20.8) | 0.067 |